Diabetes Core Update Podcasts
Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals: Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20-25 minutes long and presents 4–6 recently published articles. Intended for the busy health care professional who has little time to review journal articles in depth Diabetes Core Update discusses how the latest research and information published in ADA journals are relevant to clinical practice and can be applied in a treatment setting.
Diabetes Core Update podcasts are free and can be accessed through Apple Podcasts, Google Play, or RSS feed. The podcasts are also accessible for listening on your computer or mobile device and can be downloaded below.
|
Diabetes Core Update April 2022
Post Date: March 29, 2022 |
Play EpisodeThe Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Wander et al. Diabetes Care 2022;45(4):782–788. https://doi.org/10.2337/dc21-1686. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Wright et al. Diabetes Care 2022;45(4):909–918. https://doi.org/10.2337/dc21-1113. Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus. Diaz-Santana et al. Diabetes Care 2022;45(4):864–870. https://doi.org/10.2337/dc21-1430. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Rossing et al. Diabetes Care 2022;45(4):888–897. https://doi.org/10.2337/dc21-1944. Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Nelson et al. JAMA. 2022;327(2):138-150. doi:10.1001/jamanetworkopen.2021.48030. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes |
|
Diabetes Core Update March 2022
Post Date: February 28, 2022 |
Play EpisodeThe carbohydrate-insulin model: a physiological perspective on the obesity pandemic. Ludwig et al. The American Journal of Clinical Nutrition, Volume 114, Issue 6, December 2021, Pages 1873–1885. https://doi.org/10.1093/ajcn/nqab270. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Champakanath et al. Diabetes Care 2022;45(3):750–753. https://doi.org/10.2337/dc21-2004. Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Celis-Morales et al. Diabetes Care 2022;45(3):634–641. https://doi.org/10.2337/dc21-0601. Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Palanca et al. Diabetes Care 2022;45(3):650–658. https://doi.org/10.2337/dc21-1584. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. Rubino et al. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619. doi:10.1001/jama.2021.23619. Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018. Taha et al. Diabetes Care 2022;45(3):594–603. https://doi.org/10.2337/dc21-1757. |
|
Diabetes Core Update February 2022
Post Date: January 29, 2022 |
Play EpisodeAssociation of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study. Sjöholm et al. Diabetes Care 2022;45(2):444–450. https://doi.org/10.2337/dc21-1335. Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Johnson et al. Diabetes Care 2022;45(2):391–397. https://doi.org/10.2337/dc21-1666. Dietary Insulinemic Potential and Risk of Total and Cause-Specific Mortality in the Nurses’ Health Study and the Health Professionals Follow-up Study. Wan et al. Diabetes Care 2022;45(2):451–459. https://doi.org/10.2337/dc21-1530. 2022 National Standards for Diabetes Self-Management Education and Support. Davis et al. Diabetes Care 2022;45(2):484–494. https://doi.org/10.2337/dc21-2396. Associations of Daily Steps and Step Intensity With Incident Diabetes in a Prospective Cohort Study of Older Women: The OPACH Study. Garduno et al. Diabetes Care 2022;45(2):339–347. https://doi.org/10.2337/dc21-1202. Association of Statin Therapy Initiation With Diabetes Progression A Retrospective Matched-Cohort Study. Mansi et al. JAMA Intern Med. 2021;181(12):1562-1574. DOI: 10.1001/jamainternmed.2021.5714. |
|
Special Episode: Diabetic Neuropathy Part 1
Post Date: January 21, 2022 |
Play EpisodeIn this special three-episode series made possible by an unrestricted educational grant from Nevro, Inc., Diabetes Core Update will explore the complicated relationship between diabetes and influenza. In each episode, Dr. Neil Skolnik of Abington Memorial Hospital and the Temple University School of Medicine will discuss several aspects related to the diagnosis and treatment of DPN. In each episode of this three-part series, Dr. Skolnik will interview a special guest, most notably Rodica Pop-Busui, MD, PhD, of the University of Michigan. Dr. Busui is the editor and lead author of ADA’s January 2022 clinical compendium on the diagnosis and management of painful DPN, which was also made possible by an unrestricted educational grant from Nevro, Inc. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Rodica Pop-Busui MD, PhD. Dr. Pop-Busui is the Larry D. Soderquist Professor in Diabetes, Professor of Internal Medicine Metabolism, Endocrinology and Diabetes, Vice Chair of Clinical Research, Department of Internal Medicine, Director, Clinical Research, Mentoring and Development, Caswell Diabetes Institute, Co-Director JDRF Center of Excellence at the University of Michigan For more information about diabetic peripheral neuropathy, please see the full compendium at professional.diabetes.org/monographs. |
|
Special Episode: Explaining Time in Range Data to Patients – December 2021
Post Date: December 29, 2021 |
Play EpisodeIn this special episode on continuous glucose monitoring (CGM) and time in range Dr. Wettergreen joins our host, Dr. Neil Skolnik to discuss how to simplify and integrate CGM and time in range into primary care office practices. This special episode is supported by an independent educational grant from Abbot. Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Sara Wettergreen, PharmD, BCACP, Dr. Wettergreen is an Assistant Professor in the Department of Clinical Pharmacy at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and is a clinical pharmacist at UCHealth Lone Tree Primary Care. For more information about CGM and Time in Range, please go to: www.professional.diabetes.org/timeinrange. |
|
Diabetes Core Update January 2022
Post Date: December 27, 2021 |
Play EpisodeRemission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. McInnes et al. Diabetes Care 2022;45(1):178–185. DOI: https://doi.org/10.2337/dc21-0278. Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study. Yu et al. Diabetes Care 2022;45(1):151–159. https://doi.org/10.2337/dc21-1018. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. Agarwal et al. N Engl J Med 2021; 385:2507-2519. DOI: 10.1056/NEJMoa2110730. Changes in the Prevalence of Symptoms of Depression, Loneliness, and Insomnia in U.S. Older Adults With Type 2 Diabetes During the COVID-19 Pandemic: The Look AHEAD Study. Chao et al. Diabetes Care 2022;45(1):74–82. https://doi.org/10.2337/dc21-1179. Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2). Pugliese et al. Diabetes Care 2022;45(1):213–221. https://doi.org/10.2337/dc21-1505. Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study. Lee et al. Diabetes Care 2022;45(1):134–141. https://doi.org/10.2337/dc21-0957. |
|
Diabetes Core Update December 2021
Post Date: November 25, 2021 |
Play EpisodeThe Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Aleppo et al. Diabetes Care 2021 Dec; 44(12): 2729-2737. DOI: https://doi.org/10.2337/dc21-1304. Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden. Dehn-Hindenberg et al. Diabetes Care 2021 Dec; 44 (12): 2656-2663. https://doi.org/10.2337/dc21-0740. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Lee et al. Diabetes Care 2021 Dec; 44 (12): 2775-2782. https://doi.org/10.2337/dc21-1046. Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. Zhuo et al. JAMA Netw Open. 2021;4(10):e2130762. DOI:10.1001/jamanetworkopen.2021.30762. Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Yahyavi et al. Diabetes Care 2021 Dec; 44 (12): 2767-2774. https://doi.org/10.2337/dc21-1062. Trend of Diabetes-Related Hospital Admissions During the Transition Period From Adolescence to Adulthood in the State of California. Angel Siu Ying Nip and Maya Lodish. Diabetes Care 2021 Dec; 44 (12): 2723-2728. https://doi.org/10.2337/dc21-0555. |
|
Diabetes Core Update November 2021
Post Date: October 29, 2021 |
Play EpisodeCardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Pitt et al. N Engl J Med August 28, 2021. DOI: 10.1056/NEJMoa2110956. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Nagasu et al. Diabetes Care 2021 Nov; 44(11): 2542-2551. https://doi.org/10.2337/dc21-1081. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg et al. Diabetes Care 2021 Nov; 44(11): 2573-2581. https://doi.org/10.2337/dc21-1170. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Anker et al. N Engl J Med 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038. Patient-Centered Goal-Setting in the National Diabetes Prevention Program: A Pilot Study. Ritchie et al. Diabetes Care 2021 Nov; 44(11): 2464-2469. https://doi.org/10.2337/dc21-0677. Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia. van Gennip et al. Diabetes Care 2021 Nov; 44(11): 2493-2502. https://doi.org/10.2337/dc21-0149. |
|
Diabetes Core Update October 2021
Post Date: October 11, 2021 |
Play EpisodeReplacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. Li et al. Diabetes Care 2021 Oct; 44(10): 2403-2410. https://doi.org/10.2337/dc21-0455. Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. den Braber et al. Diabetes Care 2021 Oct; 44(10): 2238-2244. https://doi.org/10.2337/dc20-2241. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Harris et al. Diabetes Care 2021 Oct; 44(10): 2293-2301. https://doi.org/10.2337/dc21-0529. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Lind et al. Diabetes Care 2021 Oct; 44(10): 2231-2237. https://doi.org/10.2337/dc20-2439. Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. Gyldenkerne et al. Diabetes Care 2021 Oct; 44(10): 2353-2360. https://doi.org/10.2337/dc21-0383. |
|
Diabetes Core Update September 2021
Post Date: August 26, 2021 |
Play EpisodeTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías et al. N Engl J Med 2021; 385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Stempniewicz et al. Diabetes Care 2021 Sep; 44(9): 2000-2009. https://doi.org/10.2337/dc20-2715. Nutritional basis of type 2 diabetes remission. Taylor et al. BMJ 2021;374:n1449. https://doi.org/10.1136/bmj.n1449. Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Alfego et al. Diabetes Care 2021 Sep; 44(9): 2025-2032. https://doi.org/10.2337/dc21-0723. Preparing for the NASH Epidemic: A Call to Action. Kanwal et al. Diabetes Care 2021 Sep; 44(9): 2162-2172. https://doi.org/10.2337/dci21-0020. Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Gregg et al. Diabetes Care 2021 Sep; 44(9): 1916-1923. https://doi.org/10.2337/dci21-0001.
|
|
Diabetes Core Update August 2021
Post Date: July 28, 2021 |
Play EpisodeHigh Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999–2017. Park et al. Diabetes Care 2021 Aug; 44(8): 1797-1804. https://doi.org/10.2337/dc20-2708. Affect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Martens T, Beck RW, Bailey R, et al. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. JAMA. 2021;325(22):2273–2284. doi:10.1001/jama.2021.6530. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. Fang et al. N Engl J Med 2021; 384:2219-2228. DOI: 10.1056/NEJMsa2032271. Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. Salem et al. Diabetes Care 2021 Aug; 44(8): 1842-1851. https://doi.org/10.2337/dc20-2641. The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes Care 2021 Aug; 44(8): 1734-1743. https://doi.org/10.2337/dci21-0015. The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes 2021 Aug; 70(8): 1623-1633. https://doi.org/10.2337/db21-0052.
|
|
Diabetes Core Update July 2021
Post Date: July 5, 2021 |
Play EpisodeHigh Burden of Subclinical and Cardiovascular Disease Risk in Adults with Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Commodore-Mensah et al. Diabetes Care 2021 Jul; 44 (7): 1657-1663. https://doi.org/10.2337/dc20-2227. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Lingvay et al. Diabetes Care 2021 Jul; 44(7): 1595-1603. https://doi.org/10.2337/dc20-2878. Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes. Nurminen et al. Diabetes Care 2021 Jul; 44(7): 1506-1514. https://doi.org/10.2337/dc20-1719. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Bajaj et al. Diabetes Care 2021 Jul; 44(7): 1586-1594. https://doi.org/10.2337/dc20-2877. Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Morton et al. Diabetes Care 2021 Jul; 44(7): 1515-1523. https://doi.org/10.2337/dc21-0220. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Walker et al. Diabetes Care 2021 Jul; 44(7): 1480-1490. https://doi.org/10.2337/dc20-2753.
|
|
Diabetes Core Update June 2021
Post Date: May 25, 2021 |
Play EpisodeApplication of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Colling et al. Diabetes Care 2021 June; 44(6): 1443-1446. https://doi.org/10.2337/dc21-0013. Important Drop Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Roussel et al. Diabetes Care 2021 June; 44(6): 1368-1376. https://doi.org/10.2337/dc20-1690. Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes. Homer et al. Diabetes Care 2021 June; 44(6): 1254-1263. https://doi.org/10.2337/dc20-1410. Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants. Claessen et al. Diabetes Care 2021 June; 44(6): 1291-1299. https://doi.org/10.2337/dc20-2477. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Giugliano et al. Diabetes Care 2021 June; 44(6): 1353-1360. https://doi.org/10.2337/dc20-2623. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials. Silverii et al. Diabetes Obes Metab. 2021; 23: 1052– 1056. https://doi.org/10.1111/dom.14286.
|
|
Post Date: April 26, 2021 |
Play EpisodeBody Weight Changes During Pandemic-Related Shelter-in-Place in a Longitudinal Cohort Study. Lin et al. JAMA Netw Open. 2021;4(3):e212536. doi:10.1001/jamanetworkopen.2021.2536. Risk of Progression to Diabetes Among Older Adults With Prediabetes. Rooney et al. JAMA. JAMA Intern Med. 2021;181(4):511-519. doi:10.1001/jamainternmed.2020.8774. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn et al. Diabetes Care 2021 May; 44(5): 1159-1167. https://doi.org/10.2337/dc20-2492. Associations of Diet Quality and All-Cause Mortality Across Levels of Cardiometabolic Health and Disease: A 7.6-Year Prospective Analysis From the Dutch Lifelines Cohort. Vinke et al. Diabetes Care 2021 May; 44(5): 1228-1235. https://doi.org/10.2337/dc20-2709. Associations Between Exposure to Gestational Diabetes Mellitus In Utero and Daily Energy Intake, Brain Responses to Food Cues, and Adiposity in Children. Luo et al. Diabetes Care 2021 May; 44(5): 1185-1193. https://doi.org/10.2337/dc20-3006. Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Bancks et al. Diabetes Care 2021 May; 44(5): 1203-1210. https://doi.org/10.2337/dc20-2372.
|
|
Diabetes Core Update April 2021
Post Date: March 26, 2021 |
Play EpisodeOnce-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding et al. N Engl J Med 2021; 384:989-1002. doi: 10.1056/NEJMoa2032183. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial. Wadden TA, Bailey TS, Billings LK, et al. JAMA. Published online February 24, 2021. doi:10.1001/jama.2021.1831. Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Ling et al. Diabetes Care 2021 Apr; 44(4): 915-924. https://doi.org/10.2337/dc20-0876. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Persson et al. Diabetes Care 2021 Apr; 44(4): 1020-1026. https://doi.org/10.2337/dc20-1622. Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. Kammerlander et al. Diabetes Care 2021 Apr; 44(4): 1038-1045. https://doi.org/10.2337/dc20-1760. Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes. Qian et al. Diabetes Care 2021 Apr; 44(4): 1046-1054. https://doi.org/10.2337/dc20-2178. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Dave et al. Circulation. 2021;143:770–779. https://doi.org/10.1161/CIRCULATIONAHA.120.047965.
|
|
Diabetes Core Update March 2021
Post Date: February 28, 2021 |
Play EpisodeEfficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Frias et al. Diabetes Care 2021 Mar; 44(3): 765-773. https://doi.org/10.2337/dc20-1473 The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Wolf et al. Diabetes Care 2021 Mar; 44(3): 781-787. https://doi.org/10.2337/dc20-1671 Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Islam et al. Diabetes Care 2021 Mar; 44(3): 757-764. https://doi.org/10.2337/dc20-1213 Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Blonde et al. Diabetes Care 2021 Mar; 44(3): 774-780. https://doi.org/10.2337/dc20-2023 Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Patorno et al. Diabetes Care 2021 Mar; 44(3): 826-835. https://doi.org/10.2337/dc20-1464 Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. Chen et al. Diabetes Care 2021 Mar; 44(3): 663-671. https://doi.org/10.2337/dc20-1636
|
|
Diabetes Core Update February 2021
Post Date: January 27, 2021 |
Play EpisodeTime in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Lu et al. Diabetes Care 2021 Feb; 44(2): 549-555. https://doi.org/10.2337/dc20-1862 Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Lomonaco et al. Diabetes Care 2021 Feb; 44(2): 399-406. https://doi.org/10.2337/dc20-1997 Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Abdul-Ghani et al. Diabetes Care 2021 Feb; 44(2): 433-439. https://doi.org/10.2337/dc20-0978 Glycemic Control and Risk of Cellulitis. Zacay et al. Diabetes Care 2021 Feb; 44(2): 367-372. https://doi.org/10.2337/dc19-1393 Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Inzucchi et al. Diabetes Care 2021 Feb; 44(2): 586-594. https://doi.org/10.2337/dc20-1675 Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes. Wan et al. Diabetes Care 2021 Feb; 44(2): 350-357. https://doi.org/10.2337/dc20-1485
|
|
Diabetes Core Update January 2021
Post Date: December 27, 2021 |
Play EpisodeOnce-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. Rosenstock et al. N Engl J Med 2020; 383:2107-2116. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022474 The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study. Singh et al. Diabetes Care 2021 Jan; 44(1): 116-124. https://doi.org/10.2337/dc20-0571 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt et al. N Engl J Med November 16, 2020.DOI: 10.1056/NEJMoa2030186 Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015. Cheng et al. Diabetes Care 2021 Jan; 44(1): 89-97. https://doi.org/10.2337/dc20-1913 Sedentary Time and Metabolic Risk in Extremely Active Older Adults. Madden et al. Diabetes Care 2021 Jan; 44(1): 194-200. https://doi.org/10.2337/dc20-0849 Severe Hypoglycemia, Cardiac Structure and Function, and Risk of Cardiovascular Events Among Older Adults With Diabetes. Echouffo-Tcheugui et al. Diabetes Care 2021 Jan; 44(1): 248-254. https://doi.org/10.2337/dc20-0552
|
